Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
| Title: | Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. |
|---|---|
| Authors: | Buemi F; 1 Radiology Department, 'Papardo' Hospital, Messina, Italy.; Guzzardi G; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Del Sette B; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Sponghini AP; 3 Oncology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Matheoud R; 4 Medical Physics Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Soligo E; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Trisoglio A; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Carriero A; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy.; Stecco A; 2 Radiology Department, University of Eastern Piedmont, 'Maggiore della Carità' Hospital, Novara, Italy. |
| Source: | The neuroradiology journal [Neuroradiol J] 2019 Aug; Vol. 32 (4), pp. 241-249. Date of Electronic Publication: 2019 May 08. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Sage Publications Country of Publication: United States NLM ID: 101295103 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2385-1996 (Electronic) Linking ISSN: 19714009 NLM ISO Abbreviation: Neuroradiol J Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Thousand Oaks, CA : Sage Publications; Original Publication: Bologna : Centauro |
| MeSH Terms: | Antineoplastic Agents, Immunological/*therapeutic use ; Bevacizumab/*therapeutic use ; Brain Neoplasms/*drug therapy ; Glioblastoma/*drug therapy; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Glioblastoma/mortality ; Glioblastoma/pathology ; Neoplasm Recurrence, Local/pathology ; Adult ; Aged ; Aged, 80 and over ; Diffusion Magnetic Resonance Imaging ; Disease Progression ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Tumor Burden |
| Abstract: | Background: The aim of this study was to determine whether apparent diffusion coefficient (ADC) bi-component curve-fitting histogram analysis and volume percentage change (VPC) prior to bevacizumab treatment can stratify progression-free survival (PFS) and overall survival (OS) in patients with glioblastoma multiforme (GBM) on first recurrence.; Methods: We retrospectively evaluated 17 patients with recurrent GBM who received bevacizumab and fotemustine (n = 13) or only bevacizumab (n = 4) on first recurrence at our institution between December 2009 and July 2015. Both T2/FLAIR abnormalities and enhancing tumor on T1 images were mapped to the ADC images. ADC-L and ADC-M values were obtained trough bi-Gaussian curve fitting histogram analysis. Furthermore, the study population was dichotomized into two subgroups: patients displaying a reduction in enhancing tumor volume of either >55% or 41% or 0.05) in both univariate and multivariate analysis.; Conclusions: CE-ADC and CE-VPC can stratify PFS for patients with recurrent glioblastoma prior to bevacizumab treatment. |
| References: | J Clin Oncol. 1999 Aug;17(8):2572-8. (PMID: 10561324); J Clin Oncol. 2005 Feb 10;23(5):1011-27. (PMID: 15585754); Neurol Res. 2005 Jun;27(4):371-7. (PMID: 15949234); Radiology. 2005 Nov;237(2):492-9. (PMID: 16192323); J Clin Oncol. 2007 Sep 10;25(26):4104-9. (PMID: 17827460); Nat Clin Pract Oncol. 2008 Apr;5(4):220-33. (PMID: 18301415); J Neurooncol. 2009 Feb;91(3):337-51. (PMID: 19009235); J Neurooncol. 2009 Apr;92(2):149-55. (PMID: 19043778); J Clin Oncol. 2009 Feb 10;27(5):740-5. (PMID: 19114704); Neurology. 2009 Apr 7;72(14):1217-22. (PMID: 19349600); J Magn Reson Imaging. 2009 May;29(5):1199-205. (PMID: 19388113); Radiology. 2009 Jul;252(1):182-9. (PMID: 19561256); J Clin Oncol. 2009 Oct 1;27(28):4733-40. (PMID: 19720927); J Neurooncol. 2010 Feb;96(3):423-31. (PMID: 19859666); J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676); J Neurooncol. 2011 Mar;102(1):95-103. (PMID: 20798977); Curr Oncol Rep. 2011 Feb;13(1):50-6. (PMID: 21086192); J Clin Oncol. 2011 Jan 10;29(2):142-8. (PMID: 21135282); Curr Neurol Neurosci Rep. 2011 Jun;11(3):336-44. (PMID: 21234719); AJNR Am J Neuroradiol. 2011 May;32(5):882-9. (PMID: 21330401); J Neurooncol. 2012 Jan;106(1):111-9. (PMID: 21706273); Neuro Oncol. 2011 Oct;13(10):1151-61. (PMID: 21856685); J Neurooncol. 2012 Jul;108(3):491-8. (PMID: 22426926); Cancer. 2013 Oct 1;119(19):3479-88. (PMID: 23821555); Neuro Oncol. 2013 Oct;15(10):1395-404. (PMID: 23925453); Neuroradiol J. 2012 Nov;25(5):575-86. (PMID: 24029093); AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9. (PMID: 24136647); Neuroradiol J. 2008 Jun 3;21(3):350-61. (PMID: 24256904); Neuroradiol J. 2006 Jun 30;19(3):322-9. (PMID: 24351217); N Engl J Med. 2014 Feb 20;370(8):699-708. (PMID: 24552317); N Engl J Med. 2014 Feb 20;370(8):709-22. (PMID: 24552318); CNS Oncol. 2013 Jan;2(1):33-47. (PMID: 24570837); Neuro Oncol. 2014 Jul;16(7):984-90. (PMID: 24637230); J Neurooncol. 2014 Aug;119(1):149-58. (PMID: 24805151); South Asian J Cancer. 2015 Oct-Dec;4(4):163-73. (PMID: 26981507); Eur Respir J. 2017 Oct 19;50(4):. (PMID: 29051268) |
| Contributed Indexing: | Keywords: Apparent diffusion coefficient; MRI; bevacizumab; neuroradiology |
| Substance Nomenclature: | 0 (Antineoplastic Agents, Immunological); 2S9ZZM9Q9V (Bevacizumab) |
| Entry Date(s): | Date Created: 20190509 Date Completed: 20200106 Latest Revision: 20200801 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6639642 |
| DOI: | 10.1177/1971400919847184 |
| PMID: | 31066622 |
| Database: | MEDLINE |
Journal Article